{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:24:39Z","timestamp":1793287479071,"version":"4.5.0"},"reference-count":368,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.semcancer.2021.04.011","type":"journal-article","created":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T19:52:25Z","timestamp":1619293945000},"page":"141-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)"],"prefix":"10.1016","volume":"79","author":[{"given":"Grigoris","family":"Effraimidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Knigge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Oturai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5se Krogh","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5903-3355","authenticated-orcid":false,"given":"Ulla","family":"Feldt-Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2021.04.011_bib0005","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000348832","article-title":"Improving the diagnosis and management of neuroendocrine tumors: utilizing new advances in biomarker and molecular imaging science","volume":"98","author":"Giandomenico","year":"2013","journal-title":"Neuroendocrinology."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0015","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.cgh.2018.12.017","article-title":"Incidence trends of gastroenteropancreatic neuroendocrine tumors in the United States","volume":"17","author":"Lee","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/erc.0.0110001","article-title":"Neuroendocrine tumours","author":"Barakat","year":"2004","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0025","doi-asserted-by":"crossref","first-page":"R275","DOI":"10.1530\/EJE-15-0972","article-title":"GEP- NETS UPDATE: genetics of neuroendocrine tumors","volume":"174","author":"Crona","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0030","series-title":"I. Agency for Research on Cancer","article-title":"WHO classification of tumours of endocrine organs","author":"W. Health Organization","year":"2017"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0035","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2013.08.002","article-title":"Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4)","volume":"386","author":"Thakker","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/humu.20605","article-title":"Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene","volume":"29","author":"Lemos","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0045","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1086\/301729","article-title":"Characterization of mutations in patients with multiple endocrine neoplasia type 1","volume":"62","author":"Bassett","year":"1998","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0050","first-page":"4371","article-title":"Somatic mutations in MEN type 1 tumors, consistent with the Knudson \u2018Two-Hit\u2019 hypothesis","volume":"86","author":"Pannett","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0055","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1126\/science.276.5311.404","article-title":"Positional cloning of the gene for multiple endocrine neoplasia-type 1","volume":"276","author":"Chandrasekharappa","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0060","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/6.7.1177","article-title":"Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1","volume":"6","author":"Lemmens","year":"1997","journal-title":"Hum. Mol. Genetics"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0065","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jmb.2003.08.001","article-title":"Functional characterization of a promoter region in the human MEN1 tumor suppressor gene","volume":"333","author":"Fromaget","year":"2003","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0070","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1073\/pnas.95.4.1630","article-title":"Menin, the product of the MEN1 gene, is a nuclear protein","volume":"95","author":"Guru","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0075","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.tibs.2013.05.005","article-title":"Menin: a scaffold protein that controls gene expression and cell signaling","volume":"38","author":"Matkar","year":"2013","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0080","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0092-8674(00)80967-8","article-title":"Menin interacts with the AP1 transcription factor JunD and represses JunD-Activated transcription","volume":"96","author":"Agarwal","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0085","unstructured":"HGMD\u00ae gene result, (n.d.). http:\/\/www.hgmd.cf.ac.uk\/ac\/gene.php?gene=MEN1 (accessed June 18, 2020)."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0090","unstructured":"MEN1 gene homepage - Global Variome shared LOVD (n.d.). https:\/\/databases.lovd.nl\/shared\/genes\/MEN1 (accessed June 18, 2020)."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0095","unstructured":"MEN1[gene] - ClinVar - NCBI, (n.d.). https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/?term=MEN1%5Bgene%5D (accessed June 18, 2020)."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0100","unstructured":"The UMD central website, (n.d.). http:\/\/www.umd.be\/ (accessed July 6, 2020)."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0105","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cancergen.2015.12.002","article-title":"Multiple endocrine neoplasia type 1 (MEN1): an update of 208 new germline variants reported in the last nine years","volume":"209","author":"Concolino","year":"2016","journal-title":"Cancer Genet."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0110","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4158\/EP11062.RA","article-title":"Are MicroRNAs involved in the endocrine-specific pattern of tumorigenesis in multiple endocrine neoplasia type 1?","volume":"17","author":"Luzi","year":"2011","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0115","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1196\/annals.1294.020","article-title":"Molecular pathology of the MEN1 gene","volume":"1014","author":"AGARWAL","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0120","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1001\/archinte.1989.00390120069014","article-title":"Screening for the multiple endocrine neoplasia syndrome type I","volume":"149","author":"Vasen","year":"1989","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0125","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00005792-198607000-00003","article-title":"Multiple endocrine neoplasia type I","volume":"65","author":"MARX","year":"1986","journal-title":"Medicine"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0130","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/qjmed\/89.9.653","article-title":"Clinical studies of multiple endocrine neoplasia type 1 (MEN1)","volume":"89","author":"Trump","year":"1996","journal-title":"QJM"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0135","doi-asserted-by":"crossref","DOI":"10.1515\/CCLM.2008.165","article-title":"A novel MEN1 frameshift germline mutation in two Italian monozygotic twins","volume":"46","author":"Concolino","year":"2008","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0140","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0025-6196(12)62767-0","article-title":"Nonidentical expressions of multiple endocrine neoplasia, type I, in identical twins","volume":"61","author":"BAHN","year":"1986","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0145","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-016-0708-1","article-title":"MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients","volume":"14","author":"de Laat","year":"2016","journal-title":"BMC Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0150","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2018.00533","article-title":"The importance of an early and accurate MEN1 diagnosis","volume":"9","author":"de Laat","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0155","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1055\/s-0031-1286324","article-title":"Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients","volume":"43","author":"Ramundo","year":"2011","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0160","doi-asserted-by":"crossref","first-page":"E1089","DOI":"10.1002\/humu.21170","article-title":"Diagnostic challenges due to phenocopies: lessons from Multiple Endocrine Neoplasia type1 (MEN1)","volume":"31","author":"Turner","year":"2010","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0165","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jocd.2012.11.003","article-title":"Hereditary hyperparathyroidism syndromes","volume":"16","author":"Giusti","year":"2013","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0170","series-title":"Digestive System Tumours","author":"Board","year":"2019"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0175","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000098011","article-title":"Rare functioning pancreatic endocrine tumors","volume":"84","author":"O\u2019Toole","year":"2006","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0180","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00423-011-0739-1","article-title":"The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors","volume":"396","author":"Schimmack","year":"2011","journal-title":"Langenbecks Arch. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0185","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)","volume":"97","author":"Thakker","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0190","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/MD.0b013e3182954af1","article-title":"Causes of death and prognostic factors in multiple endocrine neoplasia type 1","volume":"92","author":"Ito","year":"2013","journal-title":"Medicine"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0195","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1210\/jc.2003-031513","article-title":"Effect of Multiple Endocrine Neoplasia Type 1 (MEN1) Gene Mutations on Premature Mortality in Familial MEN1 Syndrome with Founder Mutations","volume":"89","author":"Ebeling","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MPA.0000000000001454","article-title":"The north american neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors","volume":"49","author":"Howe","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0205","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000443171","article-title":"ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors","volume":"103","author":"Falconi","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0210","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.hpb.2018.09.016","article-title":"Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors","volume":"21","author":"Pulvirenti","year":"2019","journal-title":"HPB"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0215","article-title":"Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0220","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MED.0000000000000215","volume":"23","author":"Kidd","year":"2016","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0225","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1016\/S1470-2045(15)00186-2","article-title":"Consensus on biomarkers for neuroendocrine tumour disease","volume":"16","author":"Oberg","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0230","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1245\/s10434-010-1006-3","article-title":"Chromogranin a\u2014biological function and clinical utility in neuro endocrine tumor disease","volume":"17","author":"Modlin","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0235","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/00365521.2020.1759141","article-title":"True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours","volume":"55","author":"Rehfeld","year":"2020","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0240","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1210\/jc.2013-1800","article-title":"Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients","volume":"98","author":"de Laat","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0245","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/cen.13119","article-title":"Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients","volume":"85","author":"Qiu","year":"2016","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0250","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.ejca.2011.11.005","article-title":"Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?","volume":"48","author":"Walter","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0255","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1056\/NEJM198607313150504","article-title":"Secretion of pancreatic polypeptide in patients with pancreatic endocrine tumors","volume":"315","author":"Adrian","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0260","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF03350903","article-title":"Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors","volume":"27","author":"Panzuto","year":"2004","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0265","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/ajg.2015.160","article-title":"The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract","volume":"110","author":"Modlin","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063364","article-title":"The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood","volume":"8","author":"Modlin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0275","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ecl.2018.05.002","article-title":"The NETest","volume":"47","author":"Modlin","year":"2018","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0280","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1530\/ERC-15-0092","article-title":"Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status","volume":"22","author":"Kidd","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0285","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.annonc.2019.11.003","article-title":"A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood","volume":"31","author":"\u00d6berg","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0290","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1530\/ERC-14-0190","article-title":"A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection","volume":"21","author":"Modlin","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0295","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1530\/EC-19-0030","article-title":"NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging","volume":"8","author":"Malczewska","year":"2019","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0300","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1210\/jc.2018-01804","article-title":"Blood mRNA measurement (NETest) for neuroendocrine tumor diagnosis of image-negative liver metastatic disease","volume":"104","author":"Malczewska","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0305","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1634\/theoncologist.2017-0623","article-title":"Assessment of NETest clinical utility in a U.S. Registry\u2010based study","volume":"24","author":"Liu","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218592","article-title":"Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis","volume":"14","author":"Kidd","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0315","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2018.00740","article-title":"Blood transcript profiling for the detection of neuroendocrine tumors: results of a large independent validation study","volume":"9","author":"van Treijen","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0320","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jso.25129","article-title":"Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumors","volume":"118","author":"Gen\u00e7","year":"2018","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0325","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.surg.2015.06.056","article-title":"Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies","volume":"159","author":"Modlin","year":"2016","journal-title":"Surgery"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0330","doi-asserted-by":"crossref","first-page":"E1437","DOI":"10.1210\/jc.2015-2792","article-title":"Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines therapy","volume":"100","author":"\u0106wik\u0142a","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0335","doi-asserted-by":"crossref","first-page":"R145","DOI":"10.1530\/ERC-19-0372","article-title":"Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature","volume":"27","author":"Sadowski","year":"2020","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0340","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1158\/1078-0432.CCR-15-1008","article-title":"Early changes in circulating tumor cells are associated with response and survival following treatment of metastatic neuroendocrine neoplasms","volume":"22","author":"Khan","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0345","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1200\/JCO.2012.44.2905","article-title":"Circulating tumor cells As prognostic markers in neuroendocrine tumors","volume":"31","author":"Khan","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0350","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41416-018-0367-4","article-title":"Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours","volume":"120","author":"Rizzo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0355","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00467","article-title":"Cell-free DNA from metastatic pancreatic neuroendocrine tumor patients contains tumor-specific mutations and copy number variations","volume":"8","author":"Boons","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0360","doi-asserted-by":"crossref","first-page":"e2224","DOI":"10.1097\/MD.0000000000002224","article-title":"High expression of MicroRNA-196a indicates poor prognosis in resected pancreatic neuroendocrine tumor","volume":"94","author":"Lee","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0365","first-page":"2249","article-title":"Global MicroRNA profiling of pancreatic neuroendocrine neoplasias","volume":"34","author":"THORNS","year":"2014","journal-title":"Anticancer Res."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0370","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1200\/JCO.2005.05.5194","article-title":"MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior","volume":"24","author":"Roldo","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0375","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1530\/EJE-18-0305","article-title":"Prognostic relevance of proliferation-related miRNAs in pancreatic neuroendocrine neoplasms","volume":"179","author":"Grolmusz","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0380","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000487326","article-title":"A comprehensive assessment of the role of miRNAs as biomarkers in gastroenteropancreatic neuroendocrine tumors","volume":"107","author":"Malczewska","year":"2018","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0385","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s12022-019-9570-y","article-title":"MiRNA-3653 is a potential tissue biomarker for increased metastatic risk in pancreatic neuroendocrine tumours","volume":"30","author":"Gill","year":"2019","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0390","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000471879","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine and hybrid imaging","volume":"105","author":"Sundin","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0395","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2214\/ajr.181.4.1810987","article-title":"CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas","volume":"181","author":"Gouya","year":"2003","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0400","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.gie.2010.08.030","article-title":"EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors","volume":"73","author":"Khashab","year":"2011","journal-title":"Gastrointest. Endosc."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0405","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000446369","article-title":"Impact of Liver and Whole-Body Diffusion-Weighted MRI for Neuroendocrine Tumors on Patient Management: A Pilot Study","volume":"104","author":"Moryoussef","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0410","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1530\/EC-17-0006","article-title":"Radiological surveillance in multiple endocrine neoplasia type 1: a double-edged sword?","volume":"6","author":"Casey","year":"2017","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0415","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00268-017-3907-9","article-title":"Limited Value of Ga-68-DOTATOC-PET-CT in Routine Screening of Patients with Multiple Endocrine Neoplasia Type 1","volume":"41","author":"Albers","year":"2017","journal-title":"World J. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0420","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.gie.2014.09.037","article-title":"EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1","volume":"81","author":"van Asselt","year":"2015","journal-title":"Gastrointest. Endosc."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0425","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1677\/erc.1.01220","article-title":"Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study","author":"Kann","year":"2006","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0430","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-0042-119402","article-title":"Growth rate of small pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: results from an endoscopic ultrasound based cohort study","volume":"49","author":"Kappelle","year":"2016","journal-title":"Endoscopy"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0435","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2967\/jnumed.109.066134","article-title":"The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-Octreotide scintigraphy","volume":"51","author":"Srirajaskanthan","year":"2010","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0440","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1097\/SLA.0b013e3181fd37e8","article-title":"The Impact of 68Ga-DOTATOC Positron Emission Tomography\/Computed Tomography on the Multimodal Management of Patients With Neuroendocrine Tumors","volume":"252","author":"Frilling","year":"2010","journal-title":"Ann. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0445","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s00330-015-3882-1","article-title":"Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET\/CT: a lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours","volume":"26","author":"Van Binnebeek","year":"2015","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0450","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.2217\/fon.14.139","article-title":"PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature","volume":"10","author":"Johnbeck","year":"2014","journal-title":"Future Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0455","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2967\/jnumed.114.142224","article-title":"Can complementary 68Ga-DOTATATE and 18F-FDG PET\/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?","volume":"55","author":"Simsek","year":"2014","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0460","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000368609","article-title":"The role of combined 68Ga-DOTANOC and 18FDG PET\/CT in the management of patients with pancreatic neuroendocrine tumors","volume":"100","author":"Partelli","year":"2014","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0465","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ijsu.2016.03.069","article-title":"Predictive prognostic value of local and distant recurrence of F-fluorodeoxyglucose positron emission tomography for pancreatic neuroendocrine tumors with reference to World Health Organization classifications (2004, 2010). Case series study","volume":"29","author":"Dur\u00e1n","year":"2016","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0470","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/MPA.0000000000000745","article-title":"Role of combined 68Ga-DOTATOC and 18F-FDG positron emission Tomography\/Computed tomography in the diagnostic workup of pancreas neuroendocrine tumors","volume":"46","author":"Cingarlini","year":"2017","journal-title":"Pancreas"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0475","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2967\/jnumed.109.069765","article-title":"Functional imaging of neuroendocrine tumors: a head-to-Head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET","volume":"51","author":"Binderup","year":"2010","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0480","first-page":"426","article-title":"The value of (68)Ga-DOTATATE PET\/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature","volume":"4","author":"Mojtahedi","year":"2014","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0485","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/1078-0432.CCR-09-1759","article-title":"18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors","volume":"16","author":"Binderup","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0490","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2967\/jnumed.114.144386","article-title":"High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation","volume":"55","author":"Bahri","year":"2014","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0495","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.2967\/jnumed.114.137166","article-title":"Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system","volume":"55","author":"Ezziddin","year":"2014","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0500","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2217\/ije.15.29","article-title":"Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies","volume":"3","author":"Ito","year":"2016","journal-title":"Int. J. Endocr. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0505","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/MPA.0000000000000825","article-title":"Treatment of pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1","volume":"46","author":"Jensen","year":"2017","journal-title":"Pancreas"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0510","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jamcollsurg.2015.04.005","article-title":"Results of 68Gallium-DOTATATE PET\/CT scanning in patients with multiple endocrine neoplasia type 1","volume":"221","author":"Sadowski","year":"2015","journal-title":"J. Am. Coll. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0515","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s12020-015-0702-y","article-title":"Role of 68Ga-DOTATATE PET\/CT in patients with multiple endocrine neoplasia type 1 (MEN1)","volume":"52","author":"Lastoria","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0520","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1210\/jc.2016-3865","article-title":"Utility of FDG-PET imaging for risk stratification of pancreatic neuroendocrine tumors in MEN1","volume":"102","author":"Kornaczewski Jackson","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0525","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1245\/s10434-012-2285-7","article-title":"Incidental detection of pancreatic neuroendocrine tumors: an analysis of incidence and outcomes","volume":"19","author":"Cheema","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0530","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.surg.2013.08.002","article-title":"Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors","volume":"155","author":"Crippa","year":"2014","journal-title":"Surgery"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0535","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1210\/jc.2013-2604","article-title":"Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors","volume":"98","author":"Gaujoux","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0540","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.surg.2011.02.022","article-title":"Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor","volume":"150","author":"Bettini","year":"2011","journal-title":"Surgery"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0545","first-page":"34","article-title":"Systematic review of active surveillance versus British","volume":"104","author":"Partelli","year":"2016","journal-title":"J. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0550","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.bpg.2012.12.003","article-title":"Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances","volume":"26","author":"Ito","year":"2012","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0555","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/01.sla.0000124290.05524.5e","article-title":"Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with zollinger-ellison syndrome?","volume":"239","author":"Norton","year":"2004","journal-title":"Ann. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0560","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ejso.2007.07.209","article-title":"Pancreatic neuroendocrine tumours","volume":"34","author":"O\u2019Grady","year":"2008","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0565","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/SLA.0000000000000348","article-title":"Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs)","volume":"259","author":"Hashim","year":"2014","journal-title":"Ann. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0570","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1007\/s11605-013-2360-9","article-title":"Nonfunctional Pancreatic Neuroendocrine Tumors <2 cm on Preoperative Imaging are Associated with a Low Incidence of Nodal Metastasis and an Excellent Overall Survival","volume":"17","author":"Toste","year":"2013","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0575","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40618-014-0219-x","article-title":"Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET","volume":"38","author":"Lombardi","year":"2014","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0580","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.surg.2015.04.035","article-title":"Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: do size and symptoms matter?","volume":"158","author":"Sallinen","year":"2015","journal-title":"Surgery"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0585","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1245\/s10434-013-3005-7","article-title":"Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size","volume":"20","author":"Kuo","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0590","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/annonc\/mdm552","article-title":"Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours","volume":"19","author":"Bettini","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0595","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archsurg.2012.1261","article-title":"Lymph nodes and survival in pancreatic neuroendocrine tumors","volume":"147","author":"Krampitz","year":"2012","journal-title":"Arch. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0600","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/bjs.6051","article-title":"Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas","volume":"95","author":"Fischer","year":"2008","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0605","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/SLA.0b013e31815b9cae","article-title":"Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors","volume":"247","author":"Bilimoria","year":"2008","journal-title":"Ann. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0610","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/jso.24338","article-title":"Pancreatic neuroendocrine tumors: preoperative factors that predict lymph node metastases to guide operative strategy","volume":"114","author":"Postlewait","year":"2016","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0615","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jso.22118","article-title":"Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes","volume":"105","author":"Roland","year":"2011","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0620","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1007\/s11605-010-1319-3","article-title":"One hundred thirty resections for pancreatic neuroendocrine tumor: evaluating the impact of minimally invasive and parenchyma-sparing techniques","volume":"14","author":"DiNorcia","year":"2010","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0625","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1007\/s11605-016-3243-7","article-title":"Prognostic value of lymph node status and extent of Lymphadenectomy in pancreatic neuroendocrine tumors confined to and extending beyond the pancreas","volume":"20","author":"Conrad","year":"2016","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0630","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ejca.2011.10.030","article-title":"Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections","volume":"48","author":"Boninsegna","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0635","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/MPA.0000000000000987","article-title":"Predictive effect of the total number of examined lymph nodes on N staging and survival in pancreatic neuroendocrine neoplasms","volume":"47","author":"Zhang","year":"2018","journal-title":"Pancreas"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0640","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.2011.35.1817","article-title":"Prognostic validity of a novel american joint committee on Cancer staging classification for pancreatic neuroendocrine tumors","volume":"29","author":"Strosberg","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0645","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000335597","article-title":"ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary","volume":"95","author":"Pavel","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0650","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1677\/ERC-08-0247","article-title":"Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience","volume":"16","author":"Scigliano","year":"2009","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0655","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","article-title":"Surgical treatment of neuroendocrine metastases to the liver","volume":"197","author":"Sarmiento","year":"2003","journal-title":"J. Am. Coll. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0660","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1245\/s10434-010-1154-5","article-title":"Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis","volume":"17","author":"Mayo","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0665","article-title":"Prior resection of the primary tumor prolongs survival after peptide receptor radionuclide therapy of advanced neuroendocrine neoplasms","author":"Kaemmerer","year":"2019","journal-title":"Ann. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0670","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/den.13058","article-title":"Outcomes after endoscopic ultrasound\u2010guided ethanol\u2010lipiodol ablation of small pancreatic neuroendocrine tumors","volume":"30","author":"Choi","year":"2018","journal-title":"Dig. Endosc."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0675","doi-asserted-by":"crossref","first-page":"158","DOI":"10.5946\/ce.2015.48.2.158","article-title":"Endoscopic ultrasonography-guided ethanol ablation for small pancreatic neuroendocrine tumors: results of a pilot study","volume":"48","author":"Park","year":"2015","journal-title":"Clin. Endosc."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0680","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.gie.2015.08.085","article-title":"EUS-guided radiofrequency ablation for management of pancreatic insulinoma by using a novel needle electrode (with videos)","volume":"83","author":"Lakhtakia","year":"2016","journal-title":"Gastrointest. Endosc."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0685","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1055\/a-0824-7067","article-title":"Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study","volume":"51","author":"Barthet","year":"2019","journal-title":"Endoscopy"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0690","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1210\/jc.2019-00282","article-title":"Endoscopic Ultrasound-Guided Radiofrequency Ablation: A New Therapeutic Approach for Pancreatic Neuroendocrine Tumors","volume":"104","author":"Oleinikov","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0695","doi-asserted-by":"crossref","first-page":"S765","DOI":"10.1016\/j.hpb.2018.06.2482","article-title":"Endoscopic ultrasound-guided radiofrequency ablation for management of benign solid pancreatic tumors","volume":"20","author":"Choi","year":"2018","journal-title":"HPB"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0700","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/MPA.0000000000000133","article-title":"Radiofrequency ablation of pancreatic neuroendocrine tumors","volume":"43","author":"Rossi","year":"2014","journal-title":"Pancreas"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0705","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.soc.2010.11.002","article-title":"Radiofrequency ablation of neuroendocrine hepatic metastasis","volume":"20","author":"Gamblin","year":"2011","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0710","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12020-013-0130-9","article-title":"Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors","volume":"47","author":"Fiore","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0715","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0720","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/SLA.0b013e3181728a45","article-title":"90Y Radioembolization for Metastatic Neuroendocrine Liver Tumors","volume":"247","author":"Rhee","year":"2008","journal-title":"Ann. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0725","doi-asserted-by":"crossref","first-page":"108743","DOI":"10.1016\/j.ejrad.2019.108743","article-title":"Imaging-guided precision medicine in non-resectable gastro-entero-pancreatic neuroendocrine tumors: a step-by-step approach","volume":"122","author":"Rozenblum","year":"2020","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0730","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.ijrobp.2011.07.041","article-title":"Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes","volume":"83","author":"Memon","year":"2012","journal-title":"Int. J. Radiat. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0735","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00259-015-3264-6","article-title":"Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases","volume":"43","author":"Barbier","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0740","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nrendo.2018.3","article-title":"Current and emerging therapies for PNETs in patients with or without MEN1","volume":"14","author":"Frost","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0745","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1677\/ERC-09-0078","article-title":"Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors","volume":"17","author":"Kwekkeboom","year":"2010","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0750","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2174\/1874471012666190201164132","article-title":"Peptide receptor radionuclide therapy for pancreatic neuroendocrine tumours","volume":"12","author":"Alsadik","year":"2019","journal-title":"Curr. Radiopharm."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0755","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0760","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0765","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.2147\/OTT.S202867","article-title":"Peptide receptor radionuclide therapy for the treatment of pancreatic neuroendocrine tumors: recent insights","volume":"13","author":"Starr","year":"2020","journal-title":"Onco. Ther."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0770","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1530\/ERC-18-0424","article-title":"Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study","author":"Carlsen","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0775","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1053\/j.seminoncol.2018.08.004","article-title":"Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors","volume":"45","author":"Ramage","year":"2018","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0780","doi-asserted-by":"crossref","first-page":"109","DOI":"10.6004\/jnccn.2015.0012","article-title":"Role of somatostatin analogues in the treatment of neuroendocrine tumors","volume":"13","author":"Narayanan","year":"2015","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0785","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EJE-14-0354","article-title":"GEP\u2013NETs UPDATE: Biotherapy for neuroendocrine tumours","volume":"172","author":"Alonso-Gordoa","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0790","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0795","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0800","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/cen.12411","article-title":"Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours","volume":"80","author":"Ramundo","year":"2014","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0805","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0810","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0815","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1158\/1078-0432.CCR-12-3458","article-title":"Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches","volume":"19","author":"Oberg","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0820","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000497355","article-title":"The tumor microenvironment in neuroendocrine tumors: biology and therapeutic implications","volume":"109","author":"Cives","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0830","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000491999","article-title":"Efficacy and safety of sunitinib in patients with well-differentiated pancreatic neuroendocrine tumours","volume":"107","author":"Raymond","year":"2018","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0835","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/17425255.2019.1700951","article-title":"Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors","volume":"15","author":"Fazio","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0840","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0845","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/S1470-2045(20)30496-4","article-title":"Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0850","article-title":"Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1\/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs)","volume":"37","author":"Capdevila","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0855","article-title":"Progression-free survival (PFS) and subgroups analyses of lenvatinib in patients (pts) with G1\/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs): updated results from the phase II TALENT trial (GETNE 1509)","volume":"37","author":"Capdevila","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0860","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1530\/ERC-16-0008","article-title":"A phase II study of axitinib in advanced neuroendocrine tumors","volume":"23","author":"Strosberg","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0865","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.4_suppl.228","article-title":"Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET)","volume":"35","author":"Chan","year":"2017","journal-title":"JCO"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0870","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/bjc.2013.470","article-title":"Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours","volume":"109","author":"Ahn","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0875","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(15)70136-1","article-title":"Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study","volume":"16","author":"Phan","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0880","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1093\/annonc\/mdv252","article-title":"Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)","volume":"26","author":"Grande","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0885","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.3390\/jcm9113655","article-title":"Emerging treatment options for gastroenteropancreatic neuroendocrine tumors","volume":"9","author":"Cives","year":"2020","journal-title":"JCM"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0890","doi-asserted-by":"crossref","DOI":"10.21037\/tgh.2019.12.18","article-title":"Novel immunotherapy strategies for treatment of neuroendocrine neoplasms","volume":"5","author":"Al-Toubah","year":"2020","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0895","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ctrv.2018.10.008","article-title":"Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis","volume":"71","author":"Pozzari","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0900","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000443172","article-title":"ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas","volume":"103","author":"Garcia-Carbonero","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0905","doi-asserted-by":"crossref","first-page":"102835","DOI":"10.1016\/j.critrevonc.2019.102835","article-title":"Pancreatic neuroendocrine neoplasms: the latest surgical and medical treatment strategies based on the current World Health Organization classification","volume":"145","author":"Ishida","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0910","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/00000658-195510000-00015","article-title":"Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas","volume":"142","author":"ZOLLINGER","year":"1955","journal-title":"Ann. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0915","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000098009","article-title":"Gastrinoma (Duodenal and Pancreatic)","volume":"84","author":"Jensen","year":"2006","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0920","doi-asserted-by":"crossref","first-page":"5440","DOI":"10.3748\/wjg.v12.i34.5440","article-title":"Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features","volume":"12","author":"Anlauf","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0925","doi-asserted-by":"crossref","first-page":"579584","DOI":"10.1007\/s00508-007-0885-1","article-title":"Gastrinoma \u2013 morphological aspects","volume":"119","author":"Kl\u00f6ppel","year":"2007","journal-title":"Wien. Klin. Wochenschr."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0930","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1210\/er.2003-0014","article-title":"The diagnosis and medical management of advanced neuroendocrine tumors","volume":"25","author":"Kaltsas","year":"2004","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0935","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/hepr.12404","article-title":"Case of primary hepatic gastrinoma: diagnostic usefulness of the selective arterial calcium injection test","volume":"45","author":"Ogawa","year":"2014","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0940","doi-asserted-by":"crossref","first-page":"8312","DOI":"10.3748\/wjg.v19.i45.8312","article-title":"Biliary tree gastrinomas in multiple endocrine neoplasia type 1 syndrome","volume":"19","author":"Tonelli","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0945","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0002-9610(84)90029-1","article-title":"The gastrinoma triangle: operative implications","volume":"147","author":"Stabile","year":"1984","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0950","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yasu.2013.02.004","article-title":"Current management of the zollinger-ellison syndrome","volume":"47","author":"Krampitz","year":"2013","journal-title":"Adv. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0955","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/cncr.23648","article-title":"Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies","volume":"113","author":"Jensen","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0960","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/01.md.0000112297.72510.32","article-title":"Multiple endocrine neoplasia type 1 and zollinger-ellison syndrome","volume":"83","author":"Gibril","year":"2004","journal-title":"Medicine"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0965","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJM199003153221103","article-title":"Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the zollinger-ellison syndrome","volume":"322","author":"Pipeleers-Marichal","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0970","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5009\/gnl.2012.6.3.287","article-title":"The current strategy for managing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1","volume":"6","author":"Niina","year":"2012","journal-title":"Gut Liver"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0975","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00005792-200011000-00004","article-title":"Zollinger-Ellison Syndrome: Clinical Presentation in 261 Patients","volume":"79","author":"Roy","year":"2000","journal-title":"Medicine"},{"key":"10.1016\/j.semcancer.2021.04.011_bib0980","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s11894-004-0067-5","article-title":"Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion","volume":"6","author":"Gibril","year":"2004","journal-title":"Curr. Gastroenterol. Rep."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0985","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1210\/jc.2005-1349","article-title":"Patients with multiple endocrine neoplasia type 1 with gastrinomas have an increased risk of severe esophageal disease including stricture and the premalignant condition, Barrett\u2019s esophagus","volume":"91","author":"Hoffmann","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0990","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2217\/bmm.13.161","article-title":"An evaluation of chromogranin A versus gastrin and progastrin in gastrinoma diagnosis and control","volume":"8","author":"Rehfeld","year":"2014","journal-title":"Biomarkers Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib0995","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/MPA.0b013e318298df75","article-title":"Secretin stimulation test for gastrin release in zollinger-ellison syndrome","volume":"42","author":"Poitras","year":"2013","journal-title":"Pancreas"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1000","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.cgh.2011.08.012","article-title":"The zollinger\u2013ellison syndrome: dangers and consequences of interrupting antisecretory treatment","volume":"10","author":"Poitras","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1005","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0090-3671(08)70130-7","volume":"2007","author":"Fahey","year":"2007","journal-title":"Yearb. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1010","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/0016-5085(80)90933-6","article-title":"Secretin injection test in the diagnosis of gastrinoma","volume":"79","author":"McGuigan","year":"1980","journal-title":"Gastroenterology."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000265936","article-title":"Diagnostic efficacy of the secretin stimulation test for the zollinger-ellison syndrome: an intra-individual comparison using different dosages in patients and controls","volume":"10","author":"Kuiper","year":"2010","journal-title":"Pancreatology."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1020","article-title":"Hyperparathyroidism: a prerequisite for Zollinger-Ellison syndrome in multiple endocrine adenomatosis Type 1\u2014report of a further family and a review of the literature","year":"1980","journal-title":"QJM: An International Journal of Medicine"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1025","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/bjs.1800631012","article-title":"The relationship of the serum gastrin and calcium concentrations in patients with multiple endocrine neoplasia type I","volume":"63","author":"Thompson","year":"1976","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1030","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/SLA.0b013e31815efda5","article-title":"Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and zollinger-ellison syndrome","volume":"247","author":"Norton","year":"2008","journal-title":"Ann. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1035","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000335591","article-title":"ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes","volume":"95","author":"Jensen","year":"2012","journal-title":"Neuroendocrinology."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1040","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s12149-012-0634-z","article-title":"Impact of Ga-68 DOTATOC PET\/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia","volume":"26","author":"Froeling","year":"2012","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1045","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/0016-5085(95)90124-8","article-title":"Determinants of metastatic rate and survival in patients with zollinger-ellison syndrome: a prospective long-term study","volume":"108","author":"Weber","year":"1995","journal-title":"Gastroenterology."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1050","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/0002-9343(94)90323-9","article-title":"Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type I","volume":"97","author":"Benya","year":"1994","journal-title":"Am. J. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1055","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jamcollsurg.2006.02.013","article-title":"50-year appraisal of gastrinoma: recommendations for staging and treatment","volume":"202","author":"Ellison","year":"2006","journal-title":"J. Am. Coll. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1060","first-page":"1","article-title":"Metastatic potential and survival of duodenal and pancreatic tumors in multiple endocrine neoplasia type 1","author":"Vinault","year":"2018","journal-title":"Ann. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1065","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/SLA.0b013e3182536339","article-title":"Partial pancreaticoduodenectomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia type 1","volume":"257","author":"Lopez","year":"2013","journal-title":"Ann. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1070","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archsurg.1992.01420090023004","article-title":"Long-term efficacy of octreotide in the treatment of zollinger-ellison syndrome","volume":"127","author":"Mozell","year":"1992","journal-title":"Arch Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1075","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2362.1993.tb00777.x","article-title":"Long-term treatment with octreotide in patients with the Zollinger-ElIison syndrome","volume":"23","author":"RUSZNIEWSKI","year":"1993","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1080","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00006676-198804000-00006","article-title":"Long-acting somatostatin (SMS 201-995) in the management of zollinger-ellison syndrome","volume":"3","author":"Ruszniewski","year":"1988","journal-title":"Pancreas."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1085","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.2169\/internalmedicine.49.3607","article-title":"Long-term suppressive effect of octreotide on progression of metastatic gastrinoma with multiple endocrine neoplasia type 1: seven-year follow up","volume":"49","author":"Yamaguchi","year":"2010","journal-title":"Intern. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1090","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0025-6196(12)62083-7","article-title":"Functioning Insulinoma\u2014Incidence, Recurrence, and Long-Term Survival of Patients: A 60-Year Study","volume":"66","author":"SERVICE","year":"1991","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1095","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000098010","article-title":"Well-differentiated pancreatic Tumor\/Carcinoma: insulinoma","volume":"84","author":"de Herder","year":"2006","journal-title":"Neuroendocrinology."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1100","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3748\/wjg.v19.i6.829","article-title":"Diagnosis and management of insulinoma","volume":"19","author":"Okabayashi","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1105","doi-asserted-by":"crossref","first-page":"9012","DOI":"10.3748\/wjg.v19.i47.9012","article-title":"Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany","volume":"19","author":"Scher\u00fcbl","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1110","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1210\/jc.2019-01204","article-title":"Surgical Management, Preoperative Tumor Localization, and Histopathology of 80 Patients Operated on for Insulinoma","volume":"104","author":"Andreassen","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1115","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1210\/jc.2008-2031","article-title":"Secular trends in the presentation and management of functioning insulinoma at the mayo clinic, 1987\u20132007","volume":"94","author":"Placzkowski","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1120","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.pan.2012.12.158","article-title":"A systematic review of localization, surgical treatment options and outcome of insulinoma","volume":"13","author":"Hafezi","year":"2013","journal-title":"Pancreatology."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1125","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/EJE-14-0878","article-title":"Long-term results of the surgical management of insulinoma patients with MEN1: a Groupe d\u2019\u00e9tude des Tumeurs Endocrines (GTE) retrospective study","volume":"172","author":"Vezzosi","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1130","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1677\/ERC-07-0221","article-title":"Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors","volume":"15","author":"Halfdanarson","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1135","doi-asserted-by":"crossref","first-page":"R121","DOI":"10.1530\/ERC-13-0482","article-title":"Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis","volume":"21","author":"Pieterman","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1140","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1365-2265.2011.04227.x","article-title":"Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of a multicentre database","volume":"76","author":"Sakurai","year":"2012","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1145","doi-asserted-by":"crossref","first-page":"E89","DOI":"10.1210\/jc.2013-1768","article-title":"Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life","volume":"99","author":"Gon\u00e7alves","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1150","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0889-8529(05)70086-4","article-title":"Diagnostic approach to adults with hypoglycemic disorders","volume":"28","author":"Service","year":"1999","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1155","first-page":"753","article-title":"Presentation, diagnostic features and glucose handling in a monocentric series of insulinomas","volume":"36","author":"Toaiari","year":"2013","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1160","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.2169\/internalmedicine.49.3854","article-title":"Glucose-responsive Insulinoma in a patient with postprandial hypoglycemia in the morning","volume":"49","author":"Iida","year":"2010","journal-title":"Intern. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1165","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6823-14-64","article-title":"Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas","volume":"14","author":"Qiao","year":"2014","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1170","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/MPA.0000000000000110","article-title":"A Systematic Review of Localization, Surgical Treatment Options, and Outcome of Insulinoma","volume":"43","author":"Mehrabi","year":"2014","journal-title":"Pancreas."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1175","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jso.21773","article-title":"Surgical management of patients with insulinomas: result of 292 cases in a single institution","volume":"103","author":"Zhao","year":"2010","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1180","doi-asserted-by":"crossref","DOI":"10.1530\/endoabs.63.P815","article-title":"Insulinoma: diagnosis and surgical management retrospective analysis of 9 cases","author":"Elleuch","year":"2019","journal-title":"EJEA."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1185","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1148\/radiology.216.1.r00jl26163","article-title":"Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection","volume":"216","author":"Ichikawa","year":"2000","journal-title":"Radiology"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1190","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0002-9610(05)80519-7","article-title":"Pancreatic insulinomas","volume":"165","author":"Menegaux","year":"1993","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1195","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ejrad.2010.09.014","article-title":"Assessment of contrast-enhanced ultrasonography in diagnosis and preoperative localization of insulinoma","volume":"80","author":"An","year":"2011","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1200","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s12020-007-0045-4","article-title":"Endoscopic ultrasonography (EUS) in the localization of insulinoma","volume":"31","author":"Sotoudehmanesh","year":"2007","journal-title":"Endocr"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1205","doi-asserted-by":"crossref","first-page":"602","DOI":"10.4158\/EP12122.OR","article-title":"Endoscopic Ultrasonography - A Sensitive Tool in the Preoperative Localization of Insulinoma","volume":"19","author":"Joseph","year":"2013","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1210","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1148\/radiology.178.1.1984311","article-title":"Insulinomas: localization with selective intraarterial injection of calcium","volume":"178","author":"Doppman","year":"1991","journal-title":"Radiology"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1215","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1210\/jc.2008-1986","article-title":"Localization of Insulinomas to Regions of the Pancreas by Intraarterial Calcium Stimulation: The NIH Experience","volume":"94","author":"Guettier","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1220","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1210\/jc.2015-2404","article-title":"Selective arterial calcium stimulation with hepatic venous sampling differentiates insulinoma from Nesidioblastosis","volume":"100","author":"Thompson","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1225","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.3748\/wjg.v19.i23.3678","article-title":"Diagnostic accuracy of endoscopic ultrasound in pancreatic neuroendocrine tumors: a systematic review and meta analysis","volume":"19","author":"Puli","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1230","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1530\/eje.1.01901","article-title":"Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies","volume":"152","author":"Vezzosi","year":"2005","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1235","first-page":"2016","article-title":"Localization of insulinoma using 68Ga-DOTATATE PET\/CT scan","author":"Nockel","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1240","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00261-014-0219-5","article-title":"Evaluation of 68Ga-DOTANOC PET\/CT imaging in a large exclusive population of pancreatic neuroendocrine tumors","volume":"40","author":"Sharma","year":"2014","journal-title":"Abdom. Imaging"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1245","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00259-003-1184-3","article-title":"Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting","volume":"30","author":"Reubi","year":"2003","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1250","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1210\/jc.2009-1082","article-title":"Glucagon-like Peptide-1 receptor imaging for localization of insulinomas","volume":"94","author":"Christ","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1255","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(13)70049-4","article-title":"Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study","volume":"1","author":"Christ","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1260","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2967\/jnumed.115.157768","article-title":"Localization of hidden insulinomas with 68Ga-DOTA-Exendin-4 PET\/CT: a pilot study","volume":"56","author":"Antwi","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1265","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1007\/s00259-018-4101-5","article-title":"Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET\/CT, SPECT\/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study","volume":"45","author":"Antwi","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1270","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1210\/jc.2013-3541","article-title":"Detection of metastatic insulinoma by positron emission tomography with [68Ga]Exendin-4\u2014a case report","volume":"99","author":"Eriksson","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1275","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2967\/jnumed.115.167445","article-title":"Glucagon-like Peptide-1 receptor PET\/CT with 68Ga-NOTA-Exendin-4 for detecting localized insulinoma: a prospective cohort study","volume":"57","author":"Luo","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1280","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2967\/jnumed.110.085142","article-title":"Glucagon-like Peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas","volume":"52","author":"Wild","year":"2011","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1285","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1097\/RLU.0000000000000447","article-title":"68Ga DOTANOC PET\/CT detects primary malignant insulinoma","volume":"40","author":"Ambrosini","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1290","article-title":"Pasireotide for malignant insulinoma","author":"Tirosh","year":"2015","journal-title":"HJ."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1295","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/cen.12253","article-title":"Comparison of two low-dose calcium infusion schedules for localization of insulinomas by selective pancreatic arterial injection with hepatic venous sampling for insulin","volume":"80","author":"Braatvedt","year":"2013","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1300","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1007\/s00330-009-1444-0","article-title":"The role of arterial stimulation and simultaneous venous sampling in addition to cross-sectional imaging for localisation of biochemically proven insulinoma","volume":"19","author":"Morganstein","year":"2009","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1305","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.surg.2015.03.004","article-title":"Impact of variant pancreatic arterial anatomy and overlap in regional perfusion on the interpretation of selective arterial calcium stimulation with hepatic venous sampling for preoperative localization of occult insulinoma","volume":"158","author":"Thompson","year":"2015","journal-title":"Surgery."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1310","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/MPA.0b013e3182374e08","article-title":"Surgical management of insulinomas in multiple endocrine neoplasia type 1","volume":"41","author":"Giudici","year":"2012","journal-title":"Pancreas."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1315","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.bpg.2012.12.005","article-title":"Surgery for GEP-NETs","volume":"26","author":"Knigge","year":"2012","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1320","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jss.2013.07.051","article-title":"Is laparoscopic approach for pancreatic insulinomas safe? Results of a systematic review and meta-analysis","volume":"186","author":"Su","year":"2014","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1325","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1016\/j.ijsu.2014.05.023","article-title":"Laparoscopic spleen-preserving distal pancreatectomy for insulinoma: experience of a single center","volume":"12","author":"Sciuto","year":"2014","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1330","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.3748\/wjg.v20.i17.4908","article-title":"Laparoscopic resection of pancreatic neuroendocrine tumors","volume":"20","author":"Al-Kurd","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1335","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1586\/era.13.45","article-title":"Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma","volume":"13","author":"Chen","year":"2013","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1340","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1245\/s10434-007-9566-6","article-title":"Population-based study of islet cell carcinoma","volume":"14","author":"Yao","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1345","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s005340050052","article-title":"Glucagonomas\/diabetico-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases","volume":"5","author":"Soga","year":"1998","journal-title":"J. Hepatobiliary. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1350","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0399-8320(04)95184-6","article-title":"Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas","volume":"28","author":"L\u00e9vy-Bohbot","year":"2004","journal-title":"Gastroent\u00e3\u00a9rologie Clin. Biol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1355","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/pancan.2018.0003","article-title":"Glucagonoma and Glucagonoma Syndrome: One Center\u2019s Experience of Six Cases","volume":"4","author":"Wei","year":"2018","journal-title":"J. Pancreat. Cancer"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1360","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00005792-199603000-00002","article-title":"The glucagonoma syndrome clinical and pathologic features in 21 patients","volume":"75","author":"Wermers","year":"1996","journal-title":"Medicine"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1365","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000105810","article-title":"Endocrine precursor lesions and microadenomas of the duodenum and pancreas with and without MEN1: criteria, molecular concepts and clinical significance","volume":"74","author":"Anlauf","year":"2007","journal-title":"Pathobiology."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1370","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0039-6109(16)44190-3","article-title":"Update on the diagnosis and treatment of rare neuroendocrine tumors","volume":"67","author":"Friesen","year":"1987","journal-title":"Surg. Clin. North Am."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1375","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00006676-200401000-00015","article-title":"Diagnosis and treatment of VIPoma in China","volume":"28","author":"Peng","year":"2004","journal-title":"Pancreas"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1380","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1245\/s10434-015-4901-9","article-title":"The incidence and survival of rare cancers of the thyroid, parathyroid, adrenal, and pancreas","volume":"23","author":"James","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1385","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/jnci\/djs208","article-title":"TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study","volume":"104","author":"Rindi","year":"2012","journal-title":"JNCI: J. Natl. Cancer Inst."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1390","first-page":"389","article-title":"Vipoma\/diarrheogenic syndrome: a statistical evaluation of 241 reported cases","volume":"17","author":"Soga","year":"1998","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1395","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1067\/msy.1998.92005","article-title":"Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature","volume":"124","author":"Smith","year":"1998","journal-title":"Surgery."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1400","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-213016","article-title":"VIPoma with multiple endocrine neoplasia type 1 identified as an atypical gene mutation","volume":"2015","author":"Fujiya","year":"2015","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1405","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(73)91947-8","article-title":"Vasoactive Intestinal Peptide and WATERY-DIARRH\u0152A Syndrome","volume":"302","author":"Bloom","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1410","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11307-010-0374-1","article-title":"68Ga-DOTA-NOC PET\/CT Imaging of Neuroendocrine Tumors: Comparison with 111In-DTPA-Octreotide (OctreoScan\u00ae)","volume":"13","author":"Krausz","year":"2010","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1415","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1308\/003588411X582681","article-title":"Pancreatic and peripancreatic somatostatinomas","volume":"93","author":"Williamson","year":"2011","journal-title":"Annals."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1420","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/jso.2930430414","article-title":"Pancreatic somatostatinoma: a case report and review of the literature","volume":"43","author":"Konomi","year":"1990","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1425","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1159\/000441605","article-title":"Somatostatin-immunoreactive pancreaticoduodenal neuroendocrine neoplasms: twenty-three cases evaluated according to the WHO 2010 classification","volume":"103","author":"Luna","year":"2015","journal-title":"Neuroendocrinology."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1430","first-page":"13","article-title":"Somatostatinoma\/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas","volume":"18","author":"Soga","year":"1999","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1435","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1677\/ERC-07-0157","article-title":"Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity","volume":"15","author":"Garbrecht","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1440","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.soc.2015.12.003","article-title":"Clinical presentation and diagnosis of pancreatic neuroendocrine tumors","volume":"25","author":"Anderson","year":"2016","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1445","series-title":"Goldman-Cecil Medicine","author":"Goldman","year":"2020"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1450","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/BF01297144","article-title":"Clinical pathology of endocrine tumors of the pancreas","volume":"36","author":"Kimura","year":"1991","journal-title":"Digest Dis Sci."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ecl.2010.12.005","article-title":"The epidemiology of gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Lawrence","year":"2011","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1460","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1093\/annonc\/mdn351","article-title":"Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival","volume":"19","author":"Halfdanarson","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1465","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.surg.2012.08.038","article-title":"Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management","volume":"152","author":"Lee","year":"2012","journal-title":"Surgery."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1470","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/modpathol.2010.58","article-title":"Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients","volume":"23","author":"Scarpa","year":"2010","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1475","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1200\/JCO.2007.12.9809","article-title":"Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system Be simplified?","volume":"25","author":"Ferrone","year":"2007","journal-title":"JCO."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1480","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00000658-198102000-00010","article-title":"Nonfunctioning islet cell tumors","volume":"193","author":"KENT","year":"1981","journal-title":"Ann. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1485","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0344-0338(88)80043-8","article-title":"Pancreatic endocrine tumors","volume":"183","author":"Kl\u00f6ppel","year":"1988","journal-title":"Pathol. - Res. Pract."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1490","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/1097-0142(19900115)65:2<354::AID-CNCR2820650229>3.0.CO;2-N","article-title":"Islet cell carcinoma of the pancreas. A study of 98 patients","volume":"65","author":"Venkatesh","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1495","first-page":"475","article-title":"The MEA-I syndrome: an all or none phenomenon?","volume":"86","author":"Majewski","year":"1979","journal-title":"Surgery."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1500","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jso.10142","article-title":"Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms","volume":"81","author":"Gumbs","year":"2002","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1505","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/1097-0142(19860501)57:9<1824::AID-CNCR2820570920>3.0.CO;2-Q","article-title":"Pancreatic lesions and hormonal profile of pancreatic tumors in multiple endocrine neoplasia type I. An immunocytochemical study of nine patients","volume":"57","author":"Kl\u00f6ppel","year":"1986","journal-title":"Cancer."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1510","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1097\/00000478-199611000-00009","article-title":"Immunohistochemical study of 100 pancreatic tumors in 28 patients with multiple endocrine neoplasia, type I","volume":"20","author":"Le Bodic","year":"1996","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1515","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.surg.2012.02.011","article-title":"Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms","volume":"152","author":"Hamilton","year":"2012","journal-title":"Surgery."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1520","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/00000478-199709000-00012","article-title":"Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type I","volume":"21","author":"Bordi","year":"1997","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1525","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.bpg.2013.01.002","article-title":"Gastric and duodenal neuroendocrine tumours","volume":"26","author":"O\u2019Toole","year":"2012","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1530","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/cancers4010039","article-title":"Diagnosis and treatment of gastrinomas in multiple endocrine neoplasia type 1 (MEN-1)","volume":"4","author":"Pl\u00f6ckinger","year":"2012","journal-title":"Cancers."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1535","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ecl.2018.04.013","article-title":"Gastric carcinoids","volume":"47","author":"Grozinsky-Glasberg","year":"2018","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1540","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000329043","article-title":"Type I Gastric Carcinoids: A Prospective Study on Endoscopic Management and Recurrence Rate","volume":"95","author":"Merola","year":"2012","journal-title":"Neuroendocrinology."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1545","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1749-6632.1994.tb17292.x","article-title":"Endosonography of neuroendocrine tumors of the stomach, duodenum, and pancreas","volume":"733","author":"ZIMMER","year":"1994","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1550","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000443168","article-title":"ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms","volume":"103","author":"Delle Fave","year":"2016","journal-title":"Neuroendocrinology."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1555","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1016\/j.ijsu.2014.05.017","article-title":"The role of 68-Ga-DOTATOC CT-PET in surgical tactic for gastric neuroendocrine tumors treatment: our experience: a case report","volume":"12","author":"Cavallaro","year":"2014","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1560","doi-asserted-by":"crossref","DOI":"10.1007\/s11894-019-0684-7","article-title":"Gastric neuroendocrine tumors (Carcinoids)","volume":"21","author":"Gluckman","year":"2019","journal-title":"Curr. Gastroenterol. Rep."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1565","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJM200008243430805","article-title":"Treatment of type II gastric carcinoid tumors with somatostatin analogues","volume":"343","author":"Tomassetti","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1570","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/MEG.0b013e328220eae0","article-title":"Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue","volume":"19","author":"Manfredi","year":"2007","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1575","series-title":"WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart","author":"Travis","year":"2015"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1580","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","article-title":"The 2015 world health organization classification of tumors of the Thymus: continuity and changes","volume":"10","author":"Marx","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1585","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/SLA.0b013e3181dd4ec4","article-title":"Thymic neuroendocrine tumors","volume":"251","author":"Gaur","year":"2010","journal-title":"Ann. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1590","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/S0003-4975(02)03547-6","article-title":"Primary neuroendocrine tumors of the thymus","volume":"74","author":"Chaer","year":"2002","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1595","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1210\/jc.2002-021314","article-title":"Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1","volume":"88","author":"Gibril","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1600","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1210\/jc.2004-1155","article-title":"Thymic neuroendocrine carcinoma (Carcinoid) in multiple endocrine neoplasia type 1 syndrome: the italian series","volume":"90","author":"Ferolla","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1605","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00005792-199701000-00002","article-title":"Clinicopathologic studies of thymic carcinoids in multiple endocrine neoplasia type 1","volume":"76","author":"Teh","year":"1997","journal-title":"Medicine."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1610","first-page":"285","article-title":"Evaluation of 342 cases of mediastinal\/thymic carcinoids collected from literature: a comparative study between typical carcinoids and atypical varieties","volume":"5","author":"Soga","year":"1999","journal-title":"Ann. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1615","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s12672-016-0269-y","article-title":"Clinical features, treatments, and outcomes of patients with thymic carcinoids and multiple endocrine neoplasia type 1 syndrome at MD anderson Cancer center","volume":"7","author":"Christakis","year":"2016","journal-title":"HORM CANC."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1620","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jtcvs.2014.08.061","article-title":"Outcome of primary neuroendocrine tumors of the thymus: a joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases","volume":"149","author":"Filosso","year":"2015","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1625","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201cCarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"JCO."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1630","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/modpathol.3880423","article-title":"Clinicopathologic and DNA cytometric analysis of carcinoid tumors of the Thymus","volume":"14","author":"Goto","year":"2001","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1635","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1309\/3PDN-PMT5-EQTM-H0CD","article-title":"Neuroendocrine carcinomas (Carcinoid tumor) of the Thymus","volume":"114","author":"Moran","year":"2000","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1640","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.hoc.2015.09.003","article-title":"Bronchial and thymic carcinoid tumors","volume":"30","author":"Litvak","year":"2016","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1645","first-page":"246","article-title":"Carcinoid tumor of the thymus: a clinicopathologic report of seven cases with a review of the literature","volume":"55","author":"Wick","year":"1980","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1650","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2169\/internalmedicine.45.1427","article-title":"Multiple Endocrine Neoplasia Type I and Cushing\u2019s Syndrome Due to an Aggressive ACTH Producing Thymic Carcinoid","volume":"45","author":"Takagi","year":"2006","journal-title":"Intern. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1655","doi-asserted-by":"crossref","DOI":"10.1530\/endoabs.41.EP630","article-title":"A thymic carcinoid tumor causing Cushing syndrome in the setting of a multiple endocrine neoplasia syndrome type 1","author":"Gligic","year":"2016","journal-title":"EJEA"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1660","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2265.2002.01535.x","article-title":"Ectopic growth hormone-releasing hormone secretion by thymic carcinoid tumour","volume":"57","author":"Boix","year":"2002","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1665","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.athoracsur.2004.07.084","article-title":"ACTH secreting thymic carcinoid associated with multiple endocrine neoplasia type 1","volume":"81","author":"Yano","year":"2006","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1670","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.4158\/EP11038.CR","article-title":"Cushing syndrome secondary to a thymic carcinoid tumor due to multiple endocrine neoplasia type 1","volume":"17","author":"Ghazi","year":"2011","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1675","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12020-013-0141-6","article-title":"Familial Cushing syndrome due to thymic carcinoids in a multiple endocrine neoplasia type 1 kindred","volume":"47","author":"Li","year":"2014","journal-title":"Endocrine."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1680","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1378\/chest.124.1.141","article-title":"A clinicopathologic study of 12 neuroendocrine tumors arising in the Thymus","volume":"124","author":"Tiffet","year":"2003","journal-title":"Chest."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1685","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/030089161109700210","article-title":"Current role of 111In-DTPA-Octreotide scintigraphy in diagnosis of thymic masses","volume":"97","author":"Guidoccio","year":"2011","journal-title":"Tumori J."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1690","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00259-009-1349-9","article-title":"68Ga-DOTA-NOC PET\/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours","volume":"37","author":"Ambrosini","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1695","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2214\/ajr.182.2.1820511","article-title":"Positron emission tomography with FDG to show thymic carcinoid","volume":"182","author":"Groves","year":"2004","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1700","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1440-1843.2007.01161.x","article-title":"Detection of primary and metastatic lesions by [18F]fluoro-2-deoxy-D-glucose PET in a patient with thymic carcinoid","volume":"12","author":"FUJISHITA","year":"2007","journal-title":"Respirology."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1705","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1378\/chest.125.6.2368-a","article-title":"PET scanning in thymic neuroendocrine tumors","volume":"125","author":"Whitaker","year":"2004","journal-title":"Chest."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1710","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1046\/j.1365-2265.2001.01348.x","article-title":"Malignant thymic carcinoid is not prevented by transcervical thymectomy in multiple endocrine neoplasia type 1","volume":"55","author":"Burgess","year":"2001","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1715","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4132\/KoreanJPathol.2012.46.3.221","article-title":"Clinicopathological analysis of 21 thymic neuroendocrine tumors","volume":"46","author":"Ahn","year":"2012","journal-title":"Korean J. Pathol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1720","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.3892\/ol.2014.2490","article-title":"Primary neuroendocrine tumors of the thymus: clinical review of 22 cases","volume":"8","author":"SONG","year":"2014","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1725","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.athoracsur.2012.03.062","article-title":"Primary neuroendocrine tumors of the Thymus: a multicenter experience of 35 patients","volume":"94","author":"Cardillo","year":"2012","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1730","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/S1470-2045(17)30681-2","article-title":"Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial","volume":"18","author":"Ferolla","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1735","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000472255","article-title":"Thymic neuroendocrine neoplasms: biological behaviour and therapy","volume":"105","author":"Jia","year":"2017","journal-title":"Neuroendocrinology."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1740","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/annonc\/mdv041","article-title":"Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids","volume":"26","author":"Caplin","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1745","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/00000478-199808000-00003","article-title":"Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid","volume":"22","author":"Travis","year":"1998","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1750","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1210\/jc.2014-1560","article-title":"Natural course and survival of neuroendocrine tumors of Thymus and lung in MEN1 patients","volume":"99","author":"de Laat","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1755","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000435921","article-title":"Bronchopulmonary neuroendocrine neoplasms and their precursor lesions in multiple endocrine neoplasia type 1","volume":"103","author":"Bartsch","year":"2015","journal-title":"Neuroendocrinology."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1760","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/cncr.20825","article-title":"Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1","volume":"103","author":"Sachithanandan","year":"2005","journal-title":"Cancer."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1765","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s12672-015-0228-z","article-title":"Thymic and bronchial carcinoid tumors in multiple endocrine neoplasia type 1: the mayo clinic experience from 1977 to 2013","volume":"6","author":"Singh Ospina","year":"2015","journal-title":"HORM CANC."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1770","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00268-017-4135-z","article-title":"Histologically proven bronchial neuroendocrine tumors in MEN1: a GTE 51-Case cohort study","volume":"42","author":"Lecomte","year":"2017","journal-title":"World J. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1775","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/archsurg.1991.01410320017001","article-title":"The natural history of multiple endocrine neoplasia type 1","volume":"126","author":"Shepherd","year":"1991","journal-title":"Arch Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1780","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/EJE-10-0950","article-title":"Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d\u2019\u00e9tude des Tumeurs Endocrines","volume":"165","author":"Goudet","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1785","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.lungcan.2019.03.013","article-title":"Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence","volume":"132","author":"Gr\u00f8ndahl","year":"2019","journal-title":"Lung Cancer."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1790","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3390\/cancers4030777","article-title":"Neuroendocrine tumors of the lung","volume":"4","author":"Fisseler-Eckhoff","year":"2012","journal-title":"Cancers."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1795","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1148\/radiographics.22.2.g02mr01351","article-title":"Bronchial carcinoid tumors of the thorax: spectrum of radiologic findings","volume":"22","author":"Jeung","year":"2002","journal-title":"RadioGraphics"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1800","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1634\/theoncologist.2015-0198","article-title":"Challenges in the diagnosis and management of well\u2010differentiated neuroendocrine tumors of the lung (Typical and atypical carcinoid): current status and future considerations","volume":"20","author":"Wolin","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1805","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1093\/annonc\/12.suppl_2.S69","article-title":"Clinical significance of blood chromogranin A measurement in neuroendocrine tumours","volume":"12","author":"Seregni","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1810","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/0284186X.2015.1067715","article-title":"Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: state of the art","volume":"55","author":"Tabaksblat","year":"2015","journal-title":"Acta Oncol. (Madr)"},{"key":"10.1016\/j.semcancer.2021.04.011_bib1815","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/ejcts\/ezv154","article-title":"Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database","volume":"49","author":"Falcoz","year":"2015","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1820","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.thorsurg.2014.05.006","article-title":"Medical treatment of advanced thoracic neuroendocrine tumors","volume":"24","author":"Ferolla","year":"2014","journal-title":"Thorac. Surg. Clin."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1825","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1021\/cr900325h","article-title":"Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease","volume":"110","author":"Wadas","year":"2010","journal-title":"Chem. Rev."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1830","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2967\/jnumed.117.199760","article-title":"Sensitivity comparison of68Ga-OPS202 and68Ga-DOTATOC PET\/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study","volume":"59","author":"Nicolas","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1835","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2967\/jnumed.116.176636","article-title":"68 Ga\/ 177 Lu-NeoBOMB1, a novel radiolabeled GRPR antagonist for theranostic use in oncology","volume":"58","author":"Dalm","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.semcancer.2021.04.011_bib1840","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.7150\/thno.18754","article-title":"Imaging of chemokine receptor 4 expression in neuroendocrine tumors - a triple tracer comparative approach","volume":"7","author":"Werner","year":"2017","journal-title":"Theranostics"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X21001127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X21001127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:50:10Z","timestamp":1760917810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X21001127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":368,"alternative-id":["S1044579X21001127"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2021.04.011","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2021.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}